Abstract:Objective To establish progestin-resistant models of human endometrial carcinoma xenografts,and explore the role of epidermal growth factor receptor(EGFR) signaling pathway in progestin resistance of human endometrial carcinoma xenografts.Methods Thirty-six nude mice were subcutaneously injected with human endometrial carcinoma progestin-sensitive Ishikawa cells(n=18) or progestin-insensitive Ishikawa-pLWERNL cells(n=18),and human endometrial carcinoma xenografts were formed.Then,both nude mice treated with Ishikawa cells and Ishikawa-pLWERNL cells were divided into three groups,respectively(n=6),and were managed with medroxyprogesterone acetate(MPA)(MPA group),gefitinib(gefitinib group) and normal saline(control group),respectively.After treatment,wet weight of xenografts was recorded,and the expression of EGFR,progesterone receptor B(PR-B),ERK1/2,p-ERK1/2,AKT and p-AKT protein in xenograft tissues was detected by Western blotting.Results In nude mice treated with Ishikawa cells,the wet weight of xenografts in MPA group and gefitinib group was 43.0% and 31.5% lower than that in control group,respectively(P0.05).In nude mice treated with Ishikawa-pLWERNL cells,the wet weight of xenografts in gefitinib group and MPA group was 35.7% and 2.9% lower than that in control group,respectively(P0.05 and P0.05).The expression of EGFR protein in xenograft tissues treated with Ishikawa-pLWERNL cells was significantly higher than that in xenograft tissues treated with Ishikawa cells(P0.05),while that was opposite for the expression of PR-B protein(P=0.000).In xenograft tissues treated with Ishikawa cells,the expression of PR-B protein in MPA group was significantly lower than that in control group(P0.01),while there was no significant difference between gefitinib group and control group(P0.05).In xenograft tissues treated with Ishikawa-pLWERNL cells,there was no significant difference in the expression of PR-B protein among groups(P0.05).In xenograft tissues treated with Ishikawa cells,the expression of p-ERK1/2 and p-AKT protein in gefitinib group was significantly lower than that in control group and MPA group(P0.05).In xenograft tissues treated with Ishikawa-pLWERNL cells,the expression of p-ERK1/2 and p-AKT protein in gefitinib group was significantly lower than that in control group(P0.05),and the expression of p-ERK1/2 and p-AKT protein in MPA group was significantly higher than that in control group(P0.01).Conclusion The over-expressed EGFR protein can downregulate the expression of PR-B protein in Ishikawa-pLWERNL xenografts,which results in insensitivity to MPA.Gefitinib,the EGFR tyrosine kinase inhibitors,can effectively inhibit the expression of p-ERK1/2 and p-AKT protein,especially in progestin-insensitive Ishikawa-pLWERNL xenografts.

Metformin reduces progestin resistance in the transplanted endometrial tumor of the nude mice

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin Reverses Progestin Resistance In Endometrial Cancer Cells By Downregulating Gloi Expression

Metformin Promotes Progesterone Receptor Expression Via Inhibition of Mammalian Target of Rapamycin (mtor) in Endometrial Cancer Cells

Metformin reduces basal subpopulation and attenuates mammary epithelial cell stemness in FVB/N mice

Metformin Sensitizes Endometrial Cancer Cells to Progestin by Targeting TET1 to Downregulate Glyoxalase I Expression

Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating Mtor Activity in Vitro and in Vivo.

Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

DIFFERENT PROTEOMICS ANALYSIS INDICATES METFORMIN AS A NOVEL THERAPY TO AMELIORATE ENDOMETRIAL RECEPTIVITY OF ENDOMETRIOSIS

Role of Epidermal Growth Factor Receptor Signaling Pathway in Progestin Resistance of Human Endometrial Carcinoma Xenografts

Metformin Inhibits Estrogen‐dependent Endometrial Cancer Cell Growth by Activating the AMPK–FOXO1 Signal Pathway

PlGF Signaling and Macrophage Repolarization Contribute to the Anti-Neoplastic Effect of Metformin

Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells

Efficacy and Mechanism of Different Doses of Metformin on Early Endometrial Cancer Patients with Fertility Requirements

Metformin Inhibits the Development and Metastasis of Ovarian Cancer

Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.

Effects of Antidiabetic Drug Metformin on Human Breast Carcinoma Cells with Different Estrogen Receptor Expressing in Vitro

Metformin Inhibits the Function of Granulocytic Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice.